S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
Active Not Recruiting
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from retu... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/27/2025
Locations: West Virginia University Healthcare, Morgantown, West Virginia
Conditions: Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy
Completed
This study is designed to provide data on the immune response and safety of administering vaccines to relapsing multiple sclerosis (RMS) participants taking ozanimod compared to controls taking interferon-beta's or receiving no disease modifying therapies (DMTs). The data of this study will support the labels for ozanimod in multiple sclerosis (MS) because the effect of ozanimod on the vaccination response of MS participants is of interest to participants and prescribers.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/23/2025
Locations: Vaught Neurological Services, PLLC, Crab Orchard, West Virginia
Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
Completed
The purpose of this study was to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the US.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
10/10/2024
Locations: Marshall Health Site Number : 8400062, Huntington, West Virginia
Conditions: Healthy Volunteers (Meningococcal Infection)
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
Completed
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2021
Locations: Louis A Johnson VAMC, Clarksburg, West Virginia
Conditions: Heart Failure, Myocardial Infarction
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
Completed
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15 months of age.
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
12/15/2020
Locations: GSK Investigational Site, Huntington, West Virginia
Conditions: Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
Terminated
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/11/2020
Locations: WVU Medicine Spine Center, Morgantown, West Virginia +4 locations
Conditions: Staphylococcal Vaccine
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers
Completed
This is a modified single-blind, randomized, parallel-group, comparative, multicenter study to test Menactra vaccine in toddlers. Primary Objectives: * To evaluate the antibody responses induced by Measles, Mumps, Rubella, and Varicella (MMRV) vaccine when administered alone or concomitantly with Menactra vaccine. * To evaluate the antibody responses induced by Pneumococcal Conjugated Vaccine (PCV) when administered alone or concomitantly with Menactra vaccine. Observational Objectives: Safe... Read More
Gender:
ALL
Ages:
Between 9 months and 12 months
Trial Updated:
04/12/2016
Locations: Not set, Huntington, West Virginia +1 locations
Conditions: Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
Completed
This Phase 3 study is designed to demonstrate the safety and immunogenicity of MenACWY and non-interference of concomitant routine vaccines by MenACWY in an infant age group.
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
04/03/2014
Locations: 21 CAMC Health Education and Research Institute 3100 McCorkle Ave. S.E. Suite 806, Charleston, West Virginia
Conditions: Meningococcal Disease
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with radiation therapy in treating patients who have stage II or stage IIIA non-small cell lung cancer that has been completely removed in surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2013
Locations: Schiffler Cancer Center, Wheeling, West Virginia
Conditions: Lung Cancer
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
Completed
This randomized, parallel-group, open-label study will evaluate the effect of Actemra (tocilizumab) on vaccination in patients with active rheumatoid arthritis who have an inadequate response to methotrexate and who have had an inadequate clinical response or were intolerant to treatment with one or more anti-tumor necrosis factor (anti-TNF) therapies.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
11/12/2012
Locations: Not set, Clarksburg, West Virginia
Conditions: Rheumatoid Arthritis
A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation
Completed
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2012
Locations: NicVAX Investigator, Charleston, West Virginia
Conditions: Smoking Cessation